Increase in cathepsin K gene expression in Duchenne muscular dystrophy skeletal muscle

被引:1
|
作者
Kimura, Shigemi [1 ,3 ,4 ]
Miyake, Noriko [6 ]
Ozasa, Shiro [2 ]
Ueno, Hiroe [1 ]
Ohtani, Yoshinobu [1 ]
Takaoka, Yutaka [3 ,4 ,5 ]
Nishino, Ichizo [7 ]
机构
[1] Kumamoto Takumadai Rehabil Hosp, Dept Pediat, 8-2-1 Obiyama,Chuo Ku, Kumamoto 8620924, Japan
[2] Kumamoto Univ Hosp, Dept Pediat, Kumamoto, Japan
[3] Toyama Univ Hosp, Data Sci Ctr Med & Hosp Management, Toyama, Japan
[4] Kobe Univ, Dept Med Syst, Grad Sch Med, Kobe, Japan
[5] Kobe Tokiwa Univ, Fac Hlth Sci, Kobe, Japan
[6] Natl Ctr Global Hlth & Med, Res Inst, Dept Human Genet, Tokyo, Japan
[7] Natl Inst Neurosci, Natl Ctr Neurol & Psychiat, Dept Neuromuscular Res, Tokyo, Japan
关键词
Cathepsin K; Duchenne muscular dystrophy; gene expression; RNA sequence; therapy; MU-CRYSTALLIN; STRINGTIE; MATRIX; HISAT;
D O I
10.1111/neup.12995
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Dystrophinopathy is caused by alterations in the dystrophin gene. The severe phenotype, Duchenne muscular dystrophy (DMD), is caused by a lack of dystrophin in skeletal muscles, resulting in necrosis and regenerating fibers, inflammatory cells, and muscle fibrosis. Progressive muscle weakness is a characteristic finding of this condition. Here, we encountered a rare case of a 10-year-old patient with asymptomatic dystrophinopathy with no dystrophin expression and investigated the reason for the absence of muscle weakness to obtain therapeutic insights for DMD. Using RNA-seq analysis, gene expression in skeletal muscles was compared among patients with asymptomatic dystrophinopathy, three patients with typical DMD, and two patients without dystrophinopathy who were leading normal daily lives. Cathepsin K (CTSK), myosin heavy chain 3 (MYH3), and nodal modulator 3-like genes exhibited a >8-fold change, whereas crystallin mu gene (CRYM) showed a <1/8-fold change in patients with typical DMD compared with their expression in the patient with asymptomatic dystrophinopathy. Additionally, CTSK and MYH3 expression exhibited a >16-fold change (P < 0.01), whereas CRYM expression showed a <1/16-fold change (P < 0.01) in patients with typical DMD compared with their expression in those without dystrophinopathy. CTSK plays an essential role in skeletal muscle loss, fibrosis, and inflammation in response to muscles injected with cardiotoxin, one of the most common reagents that induce muscle injury. Increased CTSK expression is associated with muscle injury or necrosis in patients with DMD. The lack of muscle weakness in the patient with asymptomatic dystrophinopathy might be attributed to the low CTSK expression in the muscles. To the best of our knowledge, this is the first report to demonstrate that CTSK expression was significantly higher in the skeletal muscles of patients with DMD with a typical phenotype than in those without dystrophinopathy.
引用
收藏
页码:411 / 421
页数:11
相关论文
共 50 条
  • [1] Gene expression profiling of Duchenne muscular dystrophy skeletal muscle
    Haslett, JN
    Sanoudou, D
    Kho, AT
    Han, M
    Bennett, RR
    Kohane, IS
    Beggs, AH
    Kunkel, LM
    NEUROGENETICS, 2003, 4 (04) : 163 - 171
  • [2] Gene expression profiling of Duchenne muscular dystrophy skeletal muscle
    Judith N. Haslett
    Despina Sanoudou
    Alvin T. Kho
    Mei Han
    Richard R. Bennett
    Isaac S. Kohane
    Alan H. Beggs
    Louis M. Kunkel
    Neurogenetics, 2003, 4 : 163 - 171
  • [3] Analysis of skeletal muscle myosin synthesis and global gene expression profile in Duchenne muscular dystrophy
    Hammond, DN
    Olney, R
    Mougey, E
    Balagopal, P
    ANNALS OF NEUROLOGY, 2005, 58 : S83 - S83
  • [4] Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle
    Haslett, JN
    Sanoudou, D
    Kho, AT
    Bennett, RR
    Greenberg, SA
    Kohane, IS
    Beggs, AH
    Kunkel, LM
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (23) : 15000 - 15005
  • [5] GENE-EXPRESSION OF CALPAINS IN SKELETAL-MUSCLE OF PATIENTS WITH DUCHENNE MUSCULAR-DYSTROPHY (DMD)
    MANGAT, H
    ANANDARAJ, MPJS
    AMERICAN JOURNAL OF HUMAN GENETICS, 1991, 49 (04) : 101 - 101
  • [6] EXPRESSION OF THE MURINE DUCHENNE MUSCULAR-DYSTROPHY GENE IN MUSCLE AND BRAIN
    CHAMBERLAIN, JS
    PEARLMAN, JA
    MUZNY, DM
    GIBBS, RA
    RANIER, JE
    REEVES, AA
    CASKEY, CT
    SCIENCE, 1988, 239 (4846) : 1416 - 1418
  • [7] Oxandrolone enhances skeletal muscle myosin synthesis and alters global gene expression profile in Duchenne muscular dystrophy
    Balagopal, P
    Olney, R
    Darmaun, D
    Mougey, E
    Dokler, M
    Sieck, G
    Hammond, D
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2006, 290 (03): : E530 - E539
  • [8] NO skeletal muscle derived relaxing factor in Duchenne muscular dystrophy
    Bredt, DS
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) : 14592 - 14593
  • [9] Evaluation of skeletal muscle DTI in patients with duchenne muscular dystrophy
    Hooijmans, M. T.
    Damon, B. M.
    Froeling, M.
    Versluis, M. J.
    Burakiewicz, J.
    Verschuuren, J. J. G. M.
    Niks, E. H.
    Webb, A. G.
    Kan, H. E.
    NMR IN BIOMEDICINE, 2015, 28 (11) : 1589 - 1597
  • [10] Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophy
    Boland, BJ
    Silbert, PL
    Groover, RV
    Wollan, PC
    Silverstein, MD
    PEDIATRIC NEUROLOGY, 1996, 14 (01) : 7 - 12